Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA A Chance for 177Lu-DOTATATE Therapy?

被引：6

作者：

Nesari Javan, Farnaz ^{[1
]}

Aryana, Kamran ^{[1
]}

Askari, Emran ^{[1
]}

机构：

[1] Mashhad Univ Med Sci, Nucl Med Res Ctr, Ahmadabad St, Mashhad 9176699199, Razavi Khorasan, Iran

来源：

CLINICAL NUCLEAR MEDICINE | 2021年 / 46卷 / 09期

关键词：

mCRPC; PRLT; PRRT; Lu-177-PSMA; Lu-177-DOTATATE; PATIENT;

D O I：

10.1097/RLU.0000000000003685

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Prostate cancer with NED (neuroendocrine differentiation) may occur in various stages of the disease, which is associated with a poor prognosis and treatment resistance. We present a case of a patient with metastatic castration-resistant prostatic cancer, who was treated with 7 cycles of Lu-177-PSMA and a very good response. Although only few foci with PSMA uptake were remained in the last posttreatment images, PSA levels dramatically began to rise. This raised suspicion for NED, and Ga-68-DOTATATE was done showing sufficient uptake to consider a trial of Lu-177-DOTATATE. The patient reported pain response, and PSA levels dropped after 1 cycle of the treatment.

引用

页码：E480 / E482

页数：3

共 50 条

[1] 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation
Assadi, Majid
Pirayesh, Elahe
Rekabpour, Seyed Javad
Zohrabi, Farshad
Jafari, Esmail
Nabipour, Iraj
Esmaili, Abdolhamid
Amini, Abdullatif
Ahmadzadehfar, Hojjat
[J]. CLINICAL NUCLEAR MEDICINE, 2019, 44 (12) : 978 - 980
[2] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
Happel, C.
Kranert, W. T.
Bockisch, B.
Kratzel, U.
Baumgarten, J.
Ngoc, C. Nguyen
Garayev, E.
Gruenwald, F.
Sabet, A.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
[3] Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy
Liu, Chen
Liu, Teli
Zhang, Jingjing
Baum, Richard P.
Yang, Zhi
[J]. CLINICAL NUCLEAR MEDICINE, 2019, 44 (11) : 876 - 878
[4] Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
Abuqbeitah, Mohammad
Demir, Mustafa
Uslu-Besli, Lebriz
Yeyin, Nami
Sonmezoglu, Kerim
[J]. RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2018, 57 (01) : 55 - 61
[5] Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
Mohammad Abuqbeitah
Mustafa Demir
Lebriz Uslu-Beşli
Nami Yeyin
Kerim Sönmezoğlu
[J]. Radiation and Environmental Biophysics, 2018, 57 : 55 - 61
[6] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
Christian Mair
Boris Warwitz
Katharina Fink
Lorenza Scarpa
Bernhard Nilica
Johanna Maffey-Steffan
Sabine Buxbaum
Irene J. Virgolini
[J]. Annals of Nuclear Medicine, 2018, 32 : 499 - 502
[7] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
Mair, Christian
Warwitz, Boris
Fink, Katharina
Scarpa, Lorenza
Nilica, Bernhard
Maffey-Steffan, Johanna
Buxbaum, Sabine
Virgolini, Irene J.
[J]. ANNALS OF NUCLEAR MEDICINE, 2018, 32 (07) : 499 - 502
[8] Neuroendocrine Tumor Therapy: 177Lu-DOTATATE
Mittra, Erik S.
[J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 211 (02) : 278 - 285
[9] 177Lu-PSMA Radioligand Therapy for Prostate Cancer
Fendler, Wolfgang P.
Rahbar, Kambiz
Herrmann, Ken
Kratochwil, Clemens
Eiber, Matthias
[J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (08) : 1196 - 1200
[10] 177Lu-DOTATATE Therapy in a Case of Castrate-Resistant Prostate Cancer With Neuroendocrine Differentiation
Shu, Qiaoqiao
Li, Xianjun
Chen, Xi
Chen, Yue
Cai, Liang
[J]. CLINICAL NUCLEAR MEDICINE, 2023, 48 (08) : E371 - E373

← 1 2 3 4 5 →